Skip to main content
OpenTrials
Completed

NCT Number: NCT01342315

Topical Antifungal Treatment for Tinea Cruris

To determine if a topical antifungal cream is safe and effective for the treatment of tinea cruris

Completed

Looking for future studies?

Notify Me

Key information

Age range

12 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Belize City, Belize

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • moderate erythema, mild scaling, and moderate pruritis

Exclusion criteria

  • pregnancy and allergies

Treatment and study plan

33525

Drug

Daily dosing

Placebo

Drug

Daily dosing

Primary outcomes

  1. Proportion of patients achieving complete clearance

    Time frame: 3 weeks post-treatment

    Signs and Symptoms Severity Score and negative Potassium Hydroxide (KOH) and Culture

Secondary outcomes

  1. Proportion of patients achieving effective treatment

    Time frame: 1 week Post Treatment, 2 weeks Post Treatment, and 3 weeks Post Treatment

    Clinical Cure and Mycological Cure

Sponsors and collaborators

Lead sponsor

Medicis Global Service Corporation

Industry

Registry information

Official study title

A Randomized, Multi-Center, Double-Blind, Vehicle-Controlled Study Evaluating the Efficacy and Safety of Product 33525 in Subjects With Tinea Cruris

Important dates

Study start
2011
Primary completion
2012
Study completion
2012
First posted
Apr 27, 2011
Registry last updated
Aug 28, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.